SDC1 and breast cancer: Proteolytic cleavage of syndecan-1 promotes breast tumorigenesis, but compounds such as batimastat, benzo(α)pyrene, tranexamic acid, antithrombin III, and heparanase inhibitors can inhibit this process, potentially suppressing BC development [183].